Future options of anti-angiogenic cancer therapy..pdf (1.65 MB)
Future options of anti-angiogenic cancer therapy.
journal contributionposted on 2016-04-20, 09:30 authored by Yihai Cao
In human patients, drugs that block tumor vessel growth are widely used to treat a variety of cancer types. Many rigorous phase 3 clinical trials have demonstrated significant survival benefits; however, the addition of an anti-angiogenic component to conventional therapeutic modalities has generally produced modest survival benefits for cancer patients. Currently, it is unclear why these clinically available drugs targeting the same angiogenic pathways produce dissimilar effects in preclinical models and human patients. In this article, we discuss possible mechanisms of various anti-angiogenic drugs and the future development of optimized treatment regimens.
CitationChinese Journal of Cancer, 2016, 35 (1), 21
Author affiliation/Organisation/COLLEGE OF MEDICINE, BIOLOGICAL SCIENCES AND PSYCHOLOGY/School of Medicine/Department of Cardiovascular Sciences
- VoR (Version of Record)